SEC filings and other documents

Selinexor sNDA for myelofibrosis advances amid strong data, stable sales, and liquidity focus.

Phase III data in myelofibrosis and endometrial cancer signal major advances and rapid adoption.

Selinexor shows strong efficacy in TP53 wild-type endometrial cancer, targeting a major market.

Selinexor plus ruxolitinib achieved rapid, deep spleen reduction and early survival benefit in myelofibrosis.

All proposals passed, directors elected, and no shareholder questions were raised.

ASCO to feature promising phase III selinexor data in myelofibrosis and key regulatory updates.

Selinexor shows strong efficacy in myelofibrosis and endometrial cancer, targeting major unmet needs.

Selinexor plus ruxolitinib nearly doubled spleen response in myelofibrosis Phase 3 trial.

Strong Q1 2026 revenue, positive clinical milestones, and increased liquidity support future growth.

Selinexor plus Ruxolitinib nearly doubled spleen response and improved survival in Myelofibrosis.

Shareholders approved increasing authorized shares and adjournment flexibility at the special meeting.

2025 revenue rose, costs fell, and key myelofibrosis trial data is due in March.

Phase III SENTRY results for selinexor plus ruxolitinib could transform myelofibrosis care.

Pivotal phase III data for selinexor in myelofibrosis expected in March, targeting $1B U.S. market.

Q3 revenue up 13% YoY; SENTRY trial enrollment complete; cash runway into Q2 2026.